Agenus (AGEN) Long-Term Debt Repayments (2010 - 2026)
Agenus (AGEN) posted quarterly Long-Term Debt Repayments of $8.4 million for Q1 2026, up 236.52% year-over-year from $2.5 million in Q1 2025, and up 236.52% quarter-over-quarter from $2.5 million in Q1 2025.
Analysis
Agenus (AGEN) Long-Term Debt Repayments (2010 - 2026) Analysis & Trends
Agenus' Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at $8.4 million for Q1 2026.
- In Q1 2026, Long-Term Debt Repayments rose 236.52% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (down 63.94% YoY), while the FY2025 annual figure was $2.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q1 2026 stood at $8.4 million, up from $2.5 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $8.4 million in Q1 2026, with the low at $2.5 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Agenus | 342.07 Mn | 342.07 Mn | 34.52 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 8.41 Mn |
| Mar 31, 2025 | 2.50 Mn |
| Mar 31, 2014 | 833,333.00 |
| Dec 31, 2013 | 20.00 Mn |
| Jun 30, 2013 | -10.00 Mn |
| Dec 31, 2012 | 100,000.00 |
| Sep 30, 2012 | -100,000.00 |
| Jun 30, 2012 | -7,521.00 |
| Mar 31, 2012 | 7,521.00 |
| Dec 31, 2010 | 6.24 Mn |